- Conditions
- Atherosclerotic Cardiovascular Disease, Symptomatic Atherosclerosis, Type2 Diabetes, Familial Hypercholesterolemia
- Interventions
- Inclisiran, Evolocumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 382 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 8
- States / cities
- Jacksonville, Florida • Indianapolis, Indiana • New York, New York + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hypercholesterolemia
- Interventions
- Alirocumab, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 17
- States / cities
- Huntsville, Alabama • Mission Viejo, California • Newport Beach, California + 14 more
- Conditions
- Hypercholesterolemia, Hyperlipidemia, Familial Combined
- Interventions
- colesevelam HCl tablets and fenofibrate tablets, fenofibrate tablets and Welchol placebo tablets
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 10
- States / cities
- Longwood, Florida • Ocala, Florida • Winterpark, Florida + 7 more
- Conditions
- Familial Hypercholesterolemia
- Interventions
- Evolocumab
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Familial Hypercholesterolaemia
- Interventions
- Alert-based computerized decision support
- Device
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- Not listed
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Obesity, Type 2 Diabetes, Hyperlipidemia
- Interventions
- Low Carbohydrate Diet
- Behavioral
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Homozygous Familial Hypercholesterolemia
- Interventions
- Demographics, diagnosis type, genotype, lipid profile, treatment allocation, country of residence.
- Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- Not listed
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Hypercholesterolemia, Familial
- Interventions
- Kinetics test
- Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Metabolic Syndrome, Insulin Resistance, Obesity
- Interventions
- Exercise, Weight Loss
- Behavioral
- Lead sponsor
- Yankton Clinical Research Alliance
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 130 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Yankton, South Dakota
- Conditions
- Homozygous Familial Hypercholesterolemia (HoFH)
- Interventions
- Not listed
- Lead sponsor
- REGENXBIO Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Boca Raton, Florida
- Conditions
- Familial Hypercholesterolemia
- Interventions
- Implitapide
- Drug
- Lead sponsor
- Medical Research Laboratories International
- Industry
- Eligibility
- 8 Years to 70 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Hypercholesterolemia, Hypercholesterolemia, Familial, Hypercholesteremia in Children, Hyperlipidemia in Children
- Interventions
- Best Practice Alert, Health Maintenance Topic
- Behavioral
- Lead sponsor
- Geisinger Clinic
- Other
- Eligibility
- 9 Years to 11 Years
- Enrollment
- 13,340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Danville, Pennsylvania
- Conditions
- Familial Hypercholesterolemia
- Interventions
- Rosuvastatin, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Hyde Park, New York • Cincinnati, Ohio + 1 more
- Conditions
- Homozygous Familial Hypercholesterolemic
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 2 Years to 70 Years
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1992
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Type 2 Diabetes, Hypertension, Hyperlipidemia
- Interventions
- home health/primary care collaboration
- Behavioral
- Lead sponsor
- Albert Einstein College of Medicine
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Familial Hypercholesterolemia, Lipoprotein Types--Lp System Lp(A) Hyperlipoproteinemia, Apolipoprotein B 100, Familial Defective, High Density Lipoprotein Deficiency, Low-Density-Lipoid-Type Hyperlipoproteinemia
- Interventions
- Supportive care
- Other
- Lead sponsor
- Atlantic Health System
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Clark, New Jersey • Springfield, New Jersey
- Conditions
- Heterozygous Familial Hypercholesterolemia (HeFH), Homozygous Familial Hypercholesterolemia (HoFH), Familial Hypercholesterolemia
- Interventions
- Screening for FH
- Diagnostic Test
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Heterozygous Familial Hypercholesterolemia
- Interventions
- Placebo, Alirocumab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 7
- States / cities
- Aurora, Colorado • Hartford, Connecticut • Kansas City, Kansas + 4 more
- Conditions
- Hereditary Breast and Ovarian Cancer Syndrome, Lynch Syndrome, Familial Hypercholesterolemia
- Interventions
- Child(ren) receive an adult-onset result, Child(ren) received a pediatric-onset result, Control - Negative Result, Adolescents who received adult-onset result, Adolescents who received a pediatric-onset result, Adolescent controls - negative for familial variant
- Genetic
- Lead sponsor
- Geisinger Clinic
- Other
- Eligibility
- Not listed
- Enrollment
- 162 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Danville, Pennsylvania
- Conditions
- Hypercholesterolemia, Familial, Hyperlipidemia
- Interventions
- torcetrapib/atorvastatin, atorvastatin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 7
- States / cities
- Hartford, Connecticut • Boston, Massachusetts • Minneapolis, Minnesota + 4 more
- Conditions
- Type 2 Diabetes, Hyperlipidemia
- Interventions
- Colesevelam HCl, rosiglitazone maleate, sitagliptin phosphate
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 20
- States / cities
- La Mesa, California • Los Angeles, California • Los Gatos, California + 17 more
- Conditions
- Familial Hypercholesterolaemia
- Interventions
- rosuvastatin calcium
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 315 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Homozygous Familial Hypercholesterolemia
- Interventions
- Lomitapide
- Drug
- Lead sponsor
- Aegerion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Heterozygous Familial Hypercholesterolemia
- Interventions
- lerodalcibep
- Drug
- Lead sponsor
- LIB Therapeutics LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 478 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio